HYPOXIA-DEPENDANT MECHANISMS OF REGULATING NEOANGIOGENESIS AND APOPTOSIS IN PATIENTS WITH EARLY RECURRENT LOCALIZED PROSTATE CANCER

Objective. Examination of the expression of genes responsible for hypoxia-dependent control of transcription, neoangiogenesis, and apoptosis in tumor tissue of the prostate, in patients with localized prostate cancer (РС) with biochemical recurrence (BR) and without recurrences after radical prostatectomy (RPE).

Materials and methods. The main group included 56 patients with localized PC who had been diagnosed with BR within two years after RP. 60 patients with localized PC who did not relapse had a comparative group. 55 patients in whom operative biopsy specimens of the prostate gland were taken within healthy tissues with the removal of benign prostatic hyperplasia were combined into a control group. Determination of the expression level of the BAX, BCL2, VEGFA and HIF1α genes in tumor tissue was performed by real-time polymerase chain reaction.

Results. In patients with localized PC after RPE, development of BR is associated with an increase in the expression of BCL2, VEGFA and HIF1α genes and a decrease in the expression of the BAX gene. In patients with localized PC and early recurrence of tumor tissue through a hypoxia-dependent factor that enhances transcritical processes in tumor cells, neoangiogenesis is activated, which is associated with inhibition of apoptosis of tumor cells by enhancing the expression of the antiapoptotic gene BCL2.

Conclusion. Determination of the expression of BAX, BCL2, VEGFA and HIF1α genes in tumor tissue with localized PC allows further assessment of the risk of disease progression after surgical treatment.

1. Sergeeva N.S., Skachkova T.E., Marshutina N.V. et al. Clinical significance of PSA-associated tests in the diagnosis and staging of prostate cancer. Onkologija = Oncology 2018;(1):55–67. (In Russ.)].

2. Guliev F.A. Predictors of biochemical progression of prostate cancer. Kazanskiy medicinskiy zhurnal = Kazan Medical Journal 2017;98(6):890–4. (In Russ.).

3. Coleman W.B. Molecular pathogenesis of prostate cancer. In: Molecular Pathology. 2nd Edn. The molecular basis of human disease. Eds.: W.B. Coleman, G. Tsongalis Elsevier Inc., 2018. Pp. 555–568. DOI: 10.1016/B978-0-12-802761-5.00025-0.

4. Bethel C.R., De Marzo A.M., Nelson W.G. Molecular pathogenesis of prostate cancer: somatic, epigenetic, and genetic alterations. In: Molecular pathology. The molecular basis of human disease. Eds. W.B. Coleman, G. Tsongalis. Elsevier Inc., 2009. Pp. 489–500. DOI: 10.1016/B978-0-12-374419-7.00024-X.

5. Kogan M.I., Chibichjan M.B., Vodolazhskij D.I. Change in the expression of genetic loci in the mononuclear fraction of peripheral blood of patients with prostate cancer. Klinicheskaya onkologiya = Clinical Oncology 2012;(5):59–60. (In Russ.).

6. Tolkach Yu.V., Reva S.A., Nosov A.K. et al. Clinical significance of genetic characterization of prostate cancer: a review of literature. Onkourologiya = Oncourology 2015;(2):99–106. (In Russ.).

7. Novelli G., Ciccacci C., Borgiani P. et al. Genetic tests and genomic biomarkers: regulation, qualification and validation. Clin Cases Miner Bone Metab 2008;5(2):149–54. PMID: 22460999.

8. Komatsu N., Matsueda S., Tashiro K. et al. Gene expression profiles in peripheral blood As a biomarker in cancer patients receiving Peptide vaccination. Cancer 2012;118(12):3208–21. DOI: 10.1002/cncr.26636. PMID: 22071976.

9. Gorilovskiy L.M., Zingerenko M.B. The role of apoptosis in the pathogenesis of prostate cancer. Klinicheskaya gerontologiya = Clinical Gerontology 2007;(11):34–7. (In Russ.).

10. Tong D., Liu Q., Liu G. et al. The HIF/ PHF8/AR axis promotes prostate cancer progression. Oncogenesis 2016;5(12):e283. DOI: 10.1038/ONCSIS.2016.74. PMID: 27991916.

11. D’Amico A.V., Whittington R., Malkowicz S.B. et al. Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure. Urology 1997;49(3A Suppl):23–30. PMID: 9123732.

12. Livak K., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25(4): 402–8. DOI: 10.1006/meth.2001.1262. PMID: 11846609.

13. Chernyaev V.A. VEGF and prostate cancer. RMZh. Onkologija = RMJ. Oncology 2012;(1):17–9. (In Russ.).

14. Eisermann K., Fraizer G. The androgen receptor and VEGF: mechanisms of androgen-regulated angiogenesis in prostate cancer. Cancers (Basel) 2017;9(4):E32. DOI: 10.3390/cancers9040032. PMID: 28394264.

15. Ma T., Yang S., Jing H. et al. Apparent diffusion coefficients in prostate cancer: correlation with molecular markers Ki-67, HIF-1α and VEGF. NMR in Biomedicine 2018;31(3). DOI: 10.1002/nbm.3884. PMID: 29315957.

16. Ranasinghe W.K., Sengupta S., Williams S. et al. The effects of nonspecific HIF1α inhibitors on development of castrate resistance and metastases in prostate cancer. Cancer Med 2014;3(2):245–51. DOI: 10.1002/cam4.189. PMID: 24464861.

17. Stewart G.D., Ross J.A., McLaren D.B. et al. The relevance of a hypoxic tumour microenvironment in prostate cancer. BJU Int 2010;105(1):8–13. DOI: 10.1111/j.1464-410X.2009.08921.x. PMID: 19889065.

18. Sakai Y., Goodison S., Cao W. et al. VEGF induces expression of Bcl-2 and multiple signaling factors in microvascular endothelial cells in a prostate cancer model. World J Urol 2009;27(5):659–66. DOI: 10.1007/s00345-009-0422-0. PMID: 19495772.

19. Anvari K., Toussi M.S., Kalantari M. et al. Expression of Bcl-2 and Bax in advanced or metastatic prostate carcinoma. Urol J 2012;9(1):381–8. PMID: 22395836.

20. Renner W., Langsenlehner U., Krenn-Pilko S. et al. BCL2 genotypes and prostate cancer survival. Strahlenther Onkol 2017;193(6):466–71. DOI: 10.1007/s00066-017-1126-9. PMID: 28396899.